MARKET

NVCT

NVCT

Nuvectis Pharma, Inc.
NASDAQ
20.23
-0.77
-3.67%
After Hours: 20.08 -0.15 -0.74% 16:28 11/12 EST
OPEN
20.82
PREV CLOSE
21.00
HIGH
21.18
LOW
20.16
VOLUME
206.61K
TURNOVER
--
52 WEEK HIGH
29.28
52 WEEK LOW
5.77
MARKET CAP
695.69M
P/E (TTM)
-10.6856
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NVCT last week (1102-1106)?
Weekly Report · 3d ago
Nuvectis Pharma Insiders Enjoying US$141k Appreciation On US$1.17m Investment
Simply Wall St · 5d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Nuvectis Pharma (NVCT) and Pfizer (PFE)
TipRanks · 11/05 21:50
Analysts Are Bullish on These Healthcare Stocks: Seres Therapeutics (MCRB), Nuvectis Pharma (NVCT)
TipRanks · 11/04 17:10
Nuvectis Pharma Q3 2026 Earnings Call Transcript
Benzinga · 11/04 13:59
Nuvectis Pharma Q3 EPS $(1.02) Misses $(0.24) Estimate
Benzinga · 11/04 12:11
Press Release: Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Dow Jones · 11/04 12:01
Weekly Report: what happened at NVCT last week (1026-1030)?
Weekly Report · 11/02 10:06
More
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.

Webull offers Nuvectis Pharma Inc stock information, including NASDAQ: NVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCT stock methods without spending real money on the virtual paper trading platform.